SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: Rocketman who wrote (6287)1/15/1999 8:07:00 PM
From: Pseudo Biologist  Respond to of 9719
 
Re <<You must have been either hovering on the trigger or got lucky in your timing. >> It did stay for quite a bit in the 29 bid/29 and change ask. When I saw the release re. AFFX, I figured whatever damage there was behind the move was not worth that many points.

AIMM? what are *you* smoking? -g- Is this the chicken bones company? I can't keep them straight -g-

PB (small Xoma holder, so you can make fun back)




To: Rocketman who wrote (6287)1/15/1999 10:32:00 PM
From: scaram(o)uche  Respond to of 9719
 
Rman:

Yup.

Randy Scott knocked my socks off in the Incyte Genetics presentation. He described the price per gene sequence and the initial focus on gene rich regions and CpG islands.

It's pretty much a race, and he was just saying that a clever focus on strategy will get you the info you need faster than a focus on exhaustive mapping, but that there's a need eventually for both. The MegaBace (sp?) systems are up and running.

I'm not the person to report further, as I was learning, as I listened and questioned, about the relative quality of one company's SNPs when compared to what another company might call an SNP.

Poking around, however, and still feel that there's room for eggs in more than one basket. Genset management was a touch touchy when I asked them about CRGN's SNPs, indicating that they perhaps were of rather low quality.

Cheers! Rick